Omeros Stock Slips 27%

Shares of Omeros Corporation (OMER) are slipping over 27% on Thursday morning after the company reported narsoplimab treatment results in critically ill Covid-19 patients in I-SPY covid trial.

OMER is currently trading at $3.9312, down $1.4588 or 27.0649%, on the Nasdaq. The stock opened its trading at $5.0900 after closing Wednesday's trading at $5.3900. The stock has traded between $1.8600 and $16.3000 in the 52-week period.

Analysis in the randomized patient population shows that the addition of narsoplimab to treatment of critically ill patients with COVID-19 reduces the mortality risk. Narsoplimab showed the largest reduction in mortality risk to date across all drugs reported from the I-SPY COVID Trial.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.
Follow RTT